Your session is about to expire
← Back to Search
CAR T-cell Therapy
CAR.CD30 T cells for Non-Hodgkin's Lymphoma
Phase 1
Waitlist Available
Led By Barbara Savoldo, MD, PhD
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 years
Awards & highlights
Study Summary
This trial will test the safety of the new chimeric receptor and see if it can help the T cells kill the lymphoma cells.
Eligible Conditions
- Lymphoma
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 15 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of participants with adverse events as a measure of safety and tolerability of escalating doses of autologous activated T lymphocytes
Secondary outcome measures
Measure the response of the subjects tumor to the CAR.CD30 transduced ATL
Measure the survival of CAR.CD30 in vivo
Trial Design
1Treatment groups
Experimental Treatment
Group I: CAR.CD30 T cellsExperimental Treatment1 Intervention
Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection (IV) according to the dosing schedules: starting with the lowest cell dose (2×10^7 cells/m2) and then escalate the cell dose to the highest cell dose (2×10^8/m2) as per study design.
Find a Location
Who is running the clinical trial?
UNC Lineberger Comprehensive Cancer CenterLead Sponsor
348 Previous Clinical Trials
88,244 Total Patients Enrolled
The Methodist Hospital Research InstituteOTHER
270 Previous Clinical Trials
80,258 Total Patients Enrolled
Baylor College of MedicineOTHER
997 Previous Clinical Trials
6,002,019 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this scientific experiment actively seeking participants?
"As indicated on clinicaltrials.gov, recruitment for this trial has closed. The study was posted in October 2011 and the most recent update occured on March 16th 2022. Fortunately, there are 1783 other trials that remain active and open to patient enrollment at this time."
Answered by AI
Has the FDA signed off on CAR.CD30 T cells for use?
"Given the limited clinical data on CAR.CD30 T cells, our team has assigned them a score of 1 for safety and efficacy."
Answered by AI
Share this study with friends
Copy Link
Messenger